- Home
- CCIF vs MIST Comparison
CCIF vs MIST Comparison
Compare CCIF & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIF
- MIST
- Stock Information
- Founded
- CCIF 2011
- MIST 2003
- Country
- CCIF United States
- MIST Canada
- Employees
- CCIF N/A
- MIST N/A
- Industry
- CCIF Finance/Investors Services
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- CCIF Finance
- MIST Health Care
- Exchange
- CCIF Nasdaq
- MIST Nasdaq
- Market Cap
- CCIF 110.5M
- MIST 100.3M
- IPO Year
- CCIF N/A
- MIST N/A
- Fundamental
- Price
- CCIF $8.01
- MIST $1.81
- Analyst Decision
- CCIF
- MIST Strong Buy
- Analyst Count
- CCIF 0
- MIST 3
- Target Price
- CCIF N/A
- MIST $13.00
- AVG Volume (30 Days)
- CCIF 76.9K
- MIST 372.6K
- Earning Date
- CCIF 01-01-0001
- MIST 11-12-2024
- Dividend Yield
- CCIF 25.90%
- MIST N/A
- EPS Growth
- CCIF N/A
- MIST N/A
- EPS
- CCIF N/A
- MIST N/A
- Revenue
- CCIF N/A
- MIST N/A
- Revenue This Year
- CCIF N/A
- MIST N/A
- Revenue Next Year
- CCIF N/A
- MIST N/A
- P/E Ratio
- CCIF N/A
- MIST N/A
- Revenue Growth
- CCIF N/A
- MIST N/A
- 52 Week Low
- CCIF $7.43
- MIST $1.12
- 52 Week High
- CCIF $10.16
- MIST $2.93
- Technical
- Relative Strength Index (RSI)
- CCIF 41.94
- MIST 49.60
- Support Level
- CCIF $8.12
- MIST $1.76
- Resistance Level
- CCIF $8.25
- MIST $1.86
- Average True Range (ATR)
- CCIF 0.07
- MIST 0.10
- MACD
- CCIF 0.00
- MIST -0.02
- Stochastic Oscillator
- CCIF 32.00
- MIST 18.93
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing primarily in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting primarily of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).